EMA Withdrawn: Silgard (human papillomavirus type 6 L1 protein;human papillomavirus type 11 L1 protein;human papillomavirus type 16 L1 protein;human papillomavirus type 18 L1 protein) — Merck Sharp Dohme Ltd

View source ↗

Summary

EMA withdrawn the HPV vaccine Silgard (HPV 6/11/16/18 L1 proteins) from the market.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Condylomata Acuminata
• Immunization
• Papillomavirus Infections
• Uterine Cervical Dysplasia

Drugs mentioned

• Silgard (human papillomavirus type 6 L1 protein; human papillomavirus type 11 L1 protein; human papillomavirus type 16 L1 protein; human papillomavirus type 18 L1 protein)

Snippet

Status: Withdrawn. Therapeutic area: Papillomavirus Infections;Uterine Cervical Dysplasia;Condylomata Acuminata;Immunization. MAH: Merck Sharp Dohme Ltd. Decision date: 18/02/2019